Sakata Eiko, Shirai Yoshio, Yokoyama Naoyuki, Wakai Toshifumi, Sakata Jun, Hatakeyama Katsuyoshi
Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata City 951-8510, Japan.
World J Surg. 2006 Jun;30(6):985-91. doi: 10.1007/s00268-005-7985-8.
This study aimed to clarify the clinical significance of lymph node micrometastasis in ampullary carcinoma.
Pancreaticoduodenectomy with regional lymphadenectomy was performed for 50 consecutive patients with ampullary carcinoma. A total of 1,283 regional lymph nodes (median, 25 per patient) were examined histologically for metastases. Overt metastasis was defined as metastasis detected during routine histologic examination with hematoxylin and eosin. Micrometastasis was defined as metastasis first detected by immunohistochemistry with an antibody against cytokeratins 7 and 8. The median follow-up period was 119 months after resection.
Overt metastasis was positive in 90 lymph nodes from 27 patients. Micrometastasis was positive in 33 lymph nodes from 12 patients, all of whom also had overt nodal metastases. Patients with nodal micrometastasis had a larger number of lymph nodes with overt metastasis (median, 3.5) than those without (median, 0; P<0.001). Overt metastasis to distant nodes (superior mesenteric nodes, para-aortic nodes) was more frequent (P=0.001 and P=0.038, respectively) in patients with nodal micrometastasis. Nodal micrometastasis was found to be a strong independent prognostic factor on univariate (P<0.0001) and multivariate (relative risk, 5.085; P=0.007) analyses. From among the 27 patients with overt nodal metastasis, the outcome after resection was significantly worse in the patients with nodal micrometastasis (median survival time of 11 months) than in those without (median survival time of 63 months; P=0.0009).
Immunohistochemically detected lymph node micrometastasis indicates intensive lymphatic spread, and thus adversely affects the survival of patients with ampullary carcinoma.
本研究旨在阐明壶腹癌中淋巴结微转移的临床意义。
对50例连续的壶腹癌患者实施了胰十二指肠切除术及区域淋巴结清扫术。共对1283个区域淋巴结(中位数为每位患者25个)进行了组织学转移检查。明显转移定义为在苏木精和伊红常规组织学检查中检测到的转移。微转移定义为首次通过抗细胞角蛋白7和8抗体免疫组化检测到的转移。切除术后的中位随访期为119个月。
27例患者的90个淋巴结出现明显转移。12例患者的33个淋巴结出现微转移,所有这些患者也都有明显的淋巴结转移。有淋巴结微转移的患者出现明显转移的淋巴结数量(中位数为3.5个)多于无微转移的患者(中位数为0个;P<0.001)。有淋巴结微转移的患者远处淋巴结(肠系膜上淋巴结、腹主动脉旁淋巴结)明显转移更为频繁(分别为P=0.001和P=0.038)。在单因素(P<0.0001)和多因素(相对风险,5.085;P=0.007)分析中,淋巴结微转移被发现是一个强有力的独立预后因素。在27例有明显淋巴结转移的患者中,有淋巴结微转移的患者切除术后的结局明显比无微转移的患者差(中位生存时间为11个月)(中位生存时间为63个月;P=0.0009)。
免疫组化检测到的淋巴结微转移表明淋巴扩散强烈,因此对壶腹癌患者的生存产生不利影响。